Università degli Studi di Torino - Dipartimento di Scienza e Tecnologia del Farmaco - via Pietro Giuria 9, Torino, Italy.
Nanomedicine (Lond). 2011 Nov;6(9):1561-73. doi: 10.2217/nnm.11.52. Epub 2011 Oct 20.
Recently, 'coacervation' has been proposed as a new method to prepare fatty acid solid lipid nanoparticles (SLNs). The aim of this work was to encapsulate methotrexate, a hydrophilic anticancer drug, within SLNs obtained by coacervation, through hydrophobic ion pairing and to evaluate the potential efficacy in in vitro and in vivo breast tumor models of drug-loaded nanoparticles.
MATERIALS & METHODS: Methotrexate-loaded SLN efficacy was evaluated in vitro towards MCF-7 and Mat B-III cell lines (human and murine breast tumor cell lines). Pharmacokinetics of drug-loaded nanoparticles was evaluated in male Wistar rats and biodistribution in a breast tumor model (Mat B-III) in female Fisher rats.
Drug-loaded SLNs showed an increased cytotoxicity towards MCF-7 and Mat B-III cell lines compared with free drug. After intravenous administration, drug plasmatic concentration was increased and a major drug accumulation within neoplastic tissue was shown when the drug was loaded in SLNs, compared with drug solution alone. Encapsulation of the drug within nanoparticles also increased its oral uptake after duodenal administration.
SLNs are promising vehicles for the delivery of methotrexate, since an increase of efficacy in vitro and a preferential accumulation in breast cancer in vivo were shown. Original submitted 29 October 2010; Revision submitted 19 March 2011.
最近,“凝聚”被提议作为一种新方法来制备脂肪酸固体脂质纳米粒(SLN)。本研究旨在通过疏水离子对将亲水性抗癌药物甲氨蝶呤包封于凝聚法制备的 SLN 中,并评估其在体外和体内乳腺癌模型中载药纳米粒的潜在疗效。
评价载甲氨蝶呤 SLN 对 MCF-7 和 Mat B-III 细胞系(人及鼠乳腺癌细胞系)的体外疗效。采用雄性 Wistar 大鼠评估载药纳米粒的药代动力学,采用雌性 Fisher 大鼠的乳腺癌模型(Mat B-III)评估其体内分布。
与游离药物相比,载药 SLN 对 MCF-7 和 Mat B-III 细胞系的细胞毒性增加。与单独给予药物溶液相比,静脉给予载药纳米粒后,药物在血浆中的浓度增加,并且药物在肿瘤组织中的蓄积明显增加。与单独给予药物溶液相比,将药物包封于纳米粒中也增加了其在十二指肠给予后的口服摄取。
SLN 是递送甲氨蝶呤的有前途的载体,因为体外疗效增加,体内乳腺癌的选择性蓄积增加。原始提交日期 2010 年 10 月 29 日;修订提交日期 2011 年 3 月 19 日。